NASDAQ:LTRN Lantern Pharma Q2 2025 Earnings Report $1.71 -0.05 (-2.84%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$1.72 +0.01 (+0.58%) As of 09/11/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Lantern Pharma EPS ResultsActual EPS-$0.40Consensus EPS -$0.53Beat/MissBeat by +$0.13One Year Ago EPSN/ALantern Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALantern Pharma Announcement DetailsQuarterQ2 2025Date8/13/2025TimeBefore Market OpensConference Call DateWednesday, August 13, 2025Conference Call Time4:00PM ETUpcoming EarningsLantern Pharma's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 9:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Lantern Pharma Earnings HeadlinesLantern Pharma (LTRN) Q2 2026 Earnings Call TranscriptAugust 21, 2026 | finance.yahoo.comLantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 14, 2026 | businesswire.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.September 13 at 1:00 AM | Banyan Hill Publishing (Ad)Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of ...August 4, 2026 | finance.yahoo.comLantern Pharma Spins Off Open-Medicine AI PlatformAugust 3, 2026 | tipranks.comLantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of MedicineAugust 3, 2026 | businesswire.comSee More Lantern Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lantern Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lantern Pharma and other key companies, straight to your email. Email Address About Lantern PharmaLantern Pharma (NASDAQ:LTRN), Inc. is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment. The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need. Lead programs include LP-100, an alkylating agent advancing toward clinical evaluation in metastatic castration-resistant prostate cancer, and LP-184, a next-generation DNA-targeting compound in preclinical development for multiple solid tumors, including pancreatic and ovarian cancers. Lantern Pharma aims to streamline drug development timelines and reduce attrition rates by using AI-driven insights to inform preclinical and clinical strategies. Lantern Pharma has established collaborations with institutions such as the National Cancer Institute’s Cancer Therapy Evaluation Program and academic partners to validate its platform and progress its candidates through regulatory pathways. The company’s approach blends computational analytics with traditional pharmacology, positioning Lantern to address the growing demand for precision oncology solutions. As it advances its pipeline, Lantern Pharma seeks to deliver new therapeutic options for patients and create long-term value through a data-driven development model.View Lantern Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsPlanet Labs Has Fallen Back to Earth, But Wall Street Still Sees a ReboundAmgen Drops 10% on a Trial It Didn't Even RunOil Above $100 Is Creating a New Opportunity Beyond the Major ProducersAST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
